Bioxytran, Inc. has filed an 8-K report detailing significant corporate actions. The company amended its Certificate of Designation for Convertible Preferred Stock, requiring board and shareholder approval for conversions. Additionally, a performance-based equity award was granted to CEO David Platt, comprising 6 million shares of Convertible Preferred Stock, recognizing his contributions to the company's commercial agreements and funding initiatives. These actions are expected to positively influence investor confidence and stock performance.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.